2012-1230

ECOG E2810: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No evidence of Disease Following Metastatectomy.

Description

The purpose of this study is to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future. Pazopanib is approved by the FDA for patients who have metastatic renal cell carcinoma. However, it has not been tested in patients who have had all visible areas of their cancer removed surgically, and is considered experimental in this situation. We don't know if pazopanib will be helpful to patients in this scenario. TAdditional information on this study from ClinicalTrials.gov is urrently no standard of care for patients in this situation but careful observation without treatment is considered reasonable.

Additional information on this study from ClinicalTrials.gov


2012-1131

A041-04: A Phase 2 Randomized Study of Dalantercept in Combination with Axitinib Compared to Axitinib Alone in Patients with Advanced Renal Cell Carcinoma.

Description

To evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of dalantercept in combination with axitinib as second line treatment in patients with metastatic renal cell carcinoma.

Additional information on this study from ClinicalTrials.gov


2013-0130

SWOG S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study.

Description

The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. The current standard treatment after surgery is careful monitoring with no immediate treatment. Studies suggest that one way kidney cancer may grow is through chemical signaling through a protein called mTOR. Everolimus is a drug that stops signaling through mTOR and may tAdditional information on this study from ClinicalTrials.govforestop the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for use after surgery. In this study, you will get either everolimus or placebo (a pill with no medication). You will not get both.

Additional information on this study from ClinicalTrials.gov


2013-0778

A031203: Randomized Phase II Study Comparing Cabozantinib (NSC# 761968 And IND# 116059) With Comercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.

Description

The purpose of this study is to find out what effects sunitinib and cabozantinib have on advanced or metastatic renal cell cancer.

Additional information on this study from ClinicalTrials.gov


2013-1163

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects At High Risk Of Recurrent RCC

Description

The purpose of this research study is to investigate the safety and effectiveness of a study drug, axitinib, after surgery for patients with “high risk” recurrence of kidney cancer. Tumors need blood vessels to grow, and axitinib is thought to work by preventing new blood vessels from growing.The U.S. Food and Drug Administration has approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma, RCC) who have not responded to another drug for this type of cancer. Inlyta was also approved in Japan, Korea and other countries; however, it is still an investigational drug for adjuvant treatment for patients with high risk of recurrent RCC. It is investigational because the safety and efficacy of axitinib for the adjuvant treatment of kidney cancer has not yet been determined.

Additional information on this study from ClinicalTrials.gov


2014-0784

A4061079: A Phase IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination with MK-3475 in Patients with Advanced Renal Cell Cancer

Description

This study is for patients with an advanced type of kidney cancer known as renal cell cancer (RCC) that has not been previously treated.

The purpose of this research study is to learn about the safety and effect of the combination of the study drugs axitinib and MK-3475 and to find the best combination dose.

All subjects will take axitinib as a pill twice a day every day and receive MK-3475 as an intravenous infusion (through a needle in a vein) once every three weeks until their cancer gets worse or they experience intolerable side effects.


2013-1476

MK-3475-029: A Phase I/II clinical trial to study the safety and tolerability of MK-3475 + pegylated interferon alfa-2b (PEG-IFN) and MK-3475 + ipilimumab (IPI) in subjects with advanced melanoma (MEL) and renal cell carcinoma (RCC)

Description

This study is for patients with advanced melanoma or renal cell carcinoma (kidney cancer). Two marketed drugs (PEG-IFN and IPI) will be tested with an experimental drug (MK-3475)

The trial consists of two parts:

  1. Part 1 will involve testing different doses of the drugs in combination.
  2. Part 2 will involve testing MK-3475 given alone

Additional information on this study from ClinicalTrials.gov


2014-0964

CA209-214: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Description

This study is for patients with advanced or metastatic renal cell cancer (kidney cancer that has spread to other parts of the body).

The purpose of this study is to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab combined with ipilimumab (a medication approved in melanoma) compared with sunitinib (a medication approved in renal cell carcinoma).

Subjects will be randomized (like the flip of a coin) to receive either ipilimumab and nivolumab both given as IV infusions or sunitinib an oral medication. All subjects will be treated on this study until their disease gets worse or they experience intolerable side effects.

Additional information on this study from ClinicalTrials.gov